Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id
PublicationView,CA231978,10.3390/cancers15092552,Cancers (Basel),37174018,https://pubmed.ncbi.nlm.nih.gov/37174018,Management of Advanced Prostate Cancer in the Precision Oncology Era,2023,"Immunotherapy, Chemotherapy, Biomarkers, Theranostics, Advanced Prostate Cancer, Genomic Selection, Parp Inhibitors, Metastatic Prostate Cancer, Psma, Radioligand Therapy","Claire M Gillette, Gabriel A Yette, Scott D Cramer, Laura S Graham","Prostate cancer (PC) is the second leading cause of cancer death in men in the United States. While diversified and improved treatment options for aggressive PC have improved patient outcomes, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and an area of investigative therapeutic interest. This review will cover the seminal clinical data supporting the indication of new (Read more on Pubmed)",,Prostate Adenocarcinoma,,,Open Access,37174018
